70 TWENTYFOURSEVENBIOPHARMA Issue 1 / March 2026 SYNGENE Against a backdrop of intensifying competition among CRDMOs, Syngene International is carving out a leading position in how complex biologics are advancing within global biopharma. At this year’s CPHI in Frankfurt, chief executive Peter Bains detailed a strategy centred on scientific integration, investment in advanced modalities and the rising expectations of multinational partners. “At CPHI this year, we are showcasing the progress we have made in connecting chemistry, biology and manufacturing capabilities,” he told 24/7 BIOPHARMA. “Our goal is to give clients a single, integrated path from discovery through GMP manufacturing so that data, materials and quality oversight stay consistent throughout.” ADC capability build Syngene has made a number of investments over the past two years, one of which was a new GMP bioconjugation suite in Bengaluru. The move placed the company firmly within the high-growth market for antibody–drug conjugates (ADCs). “The new GMP bioconjugation suite allows us to complete the ADC value chain within one campus,” explained Bains. “Adding GMP-grade conjugation fills the final gap in that process.” Alongside the Bengaluru facilities, Syngene has sought to expand its payload and linker chemistry operations, as well as advances in monoclonal antibody production. Taken together, the upgrades position Syngene as a one-stop partner for ADC innovators seeking speed and regulatory simplicity. With global ADC pipelines growing at double-digit rates, and big-pharma alliances in the space surging, the move is well-timed. Oxford Biomedica’s newly announced manufacturing collaboration for VaxEquity’s ADC programmes highlights how even well-established developers are turning to specialist partners for GMP-grade conjugation and analytical support. Meanwhile, a 2025 feature in Drug Discovery News reported that, as of 2025, “more than 400 ADCs are
RkJQdWJsaXNoZXIy MjY2OTA4MA==